The clinical potential of chemokine receptor antagonists

Pharmacology and Therapeutics

Volumn 107, Issue 1, 2005, Pages 44-58

  Ribeiro, Sofia ^b   Horuk, Richard ^a  

^a BAYER AG   (Germany)

^b NONE

Author keywords

Autoimmune disease; Chemokine; Clinical trials; G protein coupled receptor; Multiple sclerosis; Receptor antagonists

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); APLAVIROC; C 4462; C 6448; CCX 105; CCX 469; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; COMPOUND 1028; CP 481715; CYCLOSPORIN; MARAVIROC; MLN 3897; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CARDIOTOXICITY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG TARGETING; ENDOMETRIOSIS; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; KIDNEY FIBROSIS; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CHEMOKINES; DIABETES MELLITUS; ENDOMETRIOSIS; FEMALE; HUMANS; MULTIPLE MYELOMA; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE;

EID: 20444375419     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.01.004     Document Type: Review

References (117)

1. Albert, R., Bruns, C., Nuninger, F., Streiff, M. B., Thoma, G., & Zerwes, H.-G. (2002). Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors. Patent Application WO2002081449 A1.
2. Albert, R., Cooke, N. G., & Thoma, G. (2004). Piperidine derivatives as CCR5 inhibitors. Patent Application WO2004031172 A1.
3. G.B. Altman, A.M. Gown, D.L. Luchtel, and C. Baker RANTES production by cultured primate endometrial epithelial cells Am J Reprod Immunol 42 1999 168 174
4. H.J. Anders, V. Vielhauer, M. Frink, Y. Linde, C.D. Cohen, and S.M. Blattner A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation J Clin Invest 109 2002 251 259
5. H.J. Anders, E. Belemezova, V. Eis, S. Segerer, V. Vielhauer, and G. Perez de Lema Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice J Am Soc Nephrol 15 2004 1504 1513
6. K. Anderson Advances in the biology of multiple myeloma: therapeutic applications Semin Oncol 26 1999 10 22
7. K.C. Anderson, J.D. Shaughnessy Jr., B. Barlogie, J.L. Harousseau, and G.D. Roodman Multiple myeloma Hematology 2002 214 240
8. G. Antinolo, R.M. Fernandez, J.A. Noval, J.L. Molini, and S. Borrego Analysis of the involvement of CCR5-Delta32 and CCR2-V64I variants in the development of endometriosis Mol Hum Reprod 10 2004 155 157
9. R. Arakaki, H. Tamamura, M. Premanathan, K. Kanbara, S. Ramanan, and K. Mochizuki T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure J Virol 73 1999 1719 1723
10. M. Baggiolini Chemokines and leukocyte traffic Nature 392 1998 565 568
11. M. Baggiolini, B. Dewald, and B. Moser Human chemokines: an update Annu Rev Immunol 15 1997 675 705
12. L.F. Barcellos, A.M. Schito, J.B. Rimmler, E. Vittinghoff, A. Shih, and R. Lincoln CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group Immunogenetics 51 2000 281 288
13. D.A. Barnes, J. Tse, M. Kaufhold, M. Owen, J. Hesselgesser, and R. Strieter Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model J Clin Invest 101 1998 2910 2919
14. B.H. Bennetts, S.M. Teutsch, M.M. Buhler, R.N. Heard, and G.J. Stewart The CCR5 deletion mutation fails to protect against multiple sclerosis Hum Immunol 58 1997 52 59
15. Bollbuck, B., Eder, J., Heng, R., Révész, L., Schlapbach, A., & Wälchli, R. (2004). 1-(4-Benzyl-piperazin-1-yl)-3-phenyl- propenone derivatives. Patent Application WO2004037796 A2.
16. Bridger, G.J., Skerlj, R.T., Kaller, A., Harwig, C., Bogucki, D., Wilson, T.R., & et al. (2002). Chemokine receptor binding heterocyclic compounds. World (PCT) patent WO-00222599.
17. M.F. Brown, M. Avery, W.H. Brissette, J.H. Chang, K. Colizza, and M. Conklyn Novel CCR1 antagonists with improved metabolic stability Bioorg Med Chem Lett 14 2004 2175 2179
18. M.M. Buhler, M. Craig, K.C. Donaghue, P. Badhwar, J. Willis, and N. Manolios CCR5 genotyping in an Australian and New Zealand type 1 diabetes cohort Autoimmunity 35 2002 457 461
19. M.J. Cameron, G.A. Arreaza, M. Grattan, C. Meagher, S. Sharif, and M.D. Burdick Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes J Immunol 165 2000 1102 1110
20. Carson, K. G., & Harriman, G. C. B. (2004). CCR1 antagonists and methods of use therefore. US Patent Application 20040106639.
21. C. Carvalho-Pinto, M.I. Garcia, L. Gomez, A. Ballesteros, A. Zaballos, and J.M. Flores Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice Eur J Immunol 34 2004 548 557
22. L.A. Castonguay, Y. Weng, W. Adolfsen, J. Di Salvo, R. Kilburn, and C.G. Caldwell Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket Biochemistry 42 2003 1544 1550
23. S.J. Choi, J.C. Cruz, F. Craig, H. Chung, R.D. Devlin, and G.D. Roodman Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood 96 2000 671 675
24. S.J. Choi, Y. Oba, Y. Gazitt, M. Alsina, J. Cruz, and J. Anderson Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease J Clin Invest 108 2001 1833 1841
25. Cumming, J., & Tucker, H. (2004). Novel piperidine derivatives as modulators of chemokine receptors. Patent Application EP1448525 A1.
26. J. Demarest, K. Adkison, S. Sparks, A. Shachoy-Clark, K. Schell, and S. Reddy Single and multiple dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of GW873140, a novel CCR5 receptor antagonist, in healthy subjects 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA 2003
27. C.P. Dorn, P.E. Finke, B. Oates, R.J. Budhu, S.G. Mills, and M. MacCoss Antagonists of the human CCR5 receptor as anti-HIV-1 agents: Part 1. Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin- 1-yl)butanes Bioorg Med Chem Lett 11 2001 259 264
28. V. Eis, B. Luckow, V. Vielhauer, J.T. Siveke, Y. Linde, and S. Segerer Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction J Am Soc Nephrol 15 2004 337 347
29. P.E. Finke, L.C. Meurer, B. Oates, S.G. Mills, M. MacCoss, and L. Malkowitz Antagonists of the human CCR5 receptor as anti-HIV-1 agents: Part 2. Structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N- (phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes Bioorg Med Chem Lett 11 2001 265 270
30. P.E. Finke, L.C. Meurer, B. Oates, S.K. Shah, J.L. Loebach, and S.G. Mills Antagonists of the human CCR5 receptor as anti-HIV-1 agents: Part 3. A proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2- (phenyl)-4-[4-(substituted)piperidin-1-yl]butanes Bioorg Med Chem Lett 11 2001 2469 2473
31. P.E. Finke, B. Oates, S.G. Mills, M. MacCoss, L. Malkowitz, and M.S. Springer Antagonists of the human CCR5 receptor as anti-HIV-1 agents: Part 4. Synthesis and structure-activity relationships for 1-[N-(methyl)-N- (phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino) piperidin-1-yl)butanes Bioorg Med Chem Lett 11 2001 2475 2479
32. M. Fischereder, B. Luckow, B. Hocher, R.P. Wuthrich, U. Rothenpieler, and H. Schneeberger CC chemokine receptor 5 and renal-transplant survival Lancet 357 2001 1758 1761
33. R. Gade-Andavolu, D.E. Comings, J. MacMurray, M. Rostamkhani, L.S. Cheng, and W.W. Tourtellotte Association of CCR5 delta32 deletion with early death in multiple sclerosis Genet Med 6 2004 126 131
34. G. Gambelunghe, M. Ghaderi, A. Brozzetti, P. Del Sindaco, B. Gharizadeh, and P. Nyren Lack of association of CCR2-64I and CCR5-Delta 32 with type 1 diabetes and latent autoimmune diabetes in adults Hum Immunol 64 2003 629 632
35. J.L. Gao, T.A. Wynn, Y. Chang, E.J. Lee, H.E. Broxmeyer, and S. Cooper Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1 J Exp Med 185 1997 1959 1968
36. C. Gerard, and B.J. Rollins Chemokines and disease Nat Immunol 2 2001 108 115
37. R.P. Gladue Discovery and characterization of a novel CCR1 antagonist, CP-481715 Inflammation Research Association Conference-Chemokines: Latest Advances and Clinical Outcomes. Boston, MA, USA (February 26-27, 2004) 2004
38. R.P. Gladue, L.A. Tylaska, W.H. Brissette, P.D. Lira, J.C. Kath, and C.S. Poss CP-481,715: a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases J Biol Chem 278 2003 40473 40480
39. R.P. Gladue, S.H. Zwillich, A.T. Clucas, and M.F. Brown CCR1 antagonists for the treatment of autoimmune diseases Curr Opin Investig Drugs 5 2004 499 504
40. C.G. Haase, S. Schmidt, and P.M. Faustmann Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis Neurosci Lett 330 2002 293 295
41. J.J. Hale, R.J. Budhu, E.B. Holson, P.E. Finke, B. Oates, and S.G. Mills 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: Part 2. Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity Bioorg Med Chem Lett 11 2001 2741 2745
42. J.J. Hale, R.J. Budhu, S.G. Mills, M. MacCoss, L. Malkowitz, and S. Siciliano 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: Part 1. Discovery of the pyrrolidine scaffold and determination of its stereochemical requirements Bioorg Med Chem Lett 11 2001 1437 1440
43. J.J. Hale, R.J. Budhu, S.G. Mills, M. MacCoss, S.L. Gould, and J.A. DeMartino 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: Part 3. Polar functionality and its effect on anti-HIV-1 activity Bioorg Med Chem Lett 12 2002 2997 3000
44. W.W. Hancock, B. Lu, W. Gao, V. Csizmadia, K. Faia, and J.A. King Requirement of the chemokine receptor CXCR3 for acute allograft rejection J Exp Med 192 2000 1515 1520
45. J.J. Haringman, M.C. Kraan, T.J. Smeets, K.H. Zwinderman, and P.P. Tak Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis Ann Rheum Dis 62 2003 715 721
46. F. Horn, E. Bettler, L. Oliveira, F. Campagne, F.E. Cohen, and G. Vriend GPCRDB information system for G protein-coupled receptors Nucleic Acids Res 31 2003 294 297
47. D. Hornung, I.P. Ryan, V.A. Chao, J.L. Vigne, E.D. Schriock, and R.N. Taylor Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells J Clin Endocrinol Metab 82 1997 1621 1628
48. D. Hornung, K. Klingel, K. Dohrn, R. Kandolf, D. Wallwiener, and R.N. Taylor Regulated on activation, normal T-cell-expressed and -secreted mRNA expression in normal endometrium and endometriotic implants: assessment of autocrine/paracrine regulation by in situ hybridization Am J Pathol 158 2001 1949 1954
49. R. Horuk Chemokine receptors and HIV-1: the fusion of two major research fields Immunol Today 20 1999 89 94
50. R. Horuk CCR1 S.K. Durum T. Hirano J. Vilcek N.A. Nicola Cytokine Database 2000 Academic Press San Diego 2027 2041
51. R. Horuk Chemokine receptors Growth Factor Rev 12 2001 313 335
52. R. Horuk, C. Clayberger, A.M. Krensky, Z. Wang, H.J. Grone, and C. Weber A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection J Biol Chem 276 2001 4199 4204
53. IDdb C-4462. The Investigational Drugs Database Drug Report 2004 < http://www.iddb.com/ >
54. IDdb C-6448. The Investigational Drugs Database Drug Report 2004 < http://www.iddb.com/ >
55. IDdb CP-481715. The Investigational Drugs Database Drug Report 2004 < http://www.iddb.com/ >
56. IDdb MLN-3897 Update. The Investigational Drugs Database Drug Report 2004 < http://www.iddb.com/ >
57. IDdb UK-427857. The Investigational Drugs Database Drug Report 2004 < http://www.iddb.com/ >
58. IDdb Chemocentryx Company Report. The Investigational Drugs Database Drug Report 2005 < http://www.iddb.com/ >
59. IDdb Sch-417690. The Investigational Drugs Database Drug Report 2005 < http://www.iddb.com/ >
60. I. Kalev, K. Oselin, P. Parlist, M. Zilmer, T. Rajasalu, and T. Podar CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes J Diabetes Its Complications 17 2003 387 391
61. K. Kanbe, T. Takemura, K. Takeuchi, Q. Chen, K. Takagishi, and K. Inoue Synovectomy reduces stromal-cell-derived factor-1 (SDF-1) which is involved in the destruction of cartilage in osteoarthritis and rheumatoid arthritis J Bone Jt Surg Br 86 2004 296 300
62. J.C. Kath, W.H. Brissette, M.F. Brown, M. Conklyn, A.P. DiRico, and P. Dorff Potent small molecule CCR1 antagonists Bioorg Med Chem Lett 14 2004 2169 2173
63. J.C. Kath, A.P. DiRico, R.P. Gladue, W.H. Martin, E.B. McElroy, and I.A. Stock The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template Bioorg Med Chem Lett 14 2004 2163 2167
64. D. Kim, L. Wang, C.G. Caldwell, P. Chen, P.E. Finke, and B. Oates Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection Bioorg Med Chem Lett 11 2001 3103 3106
65. D. Kim, L. Wang, C.G. Caldwell, P. Chen, P.E. Finke, and B. Oates Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection Bioorg Med Chem Lett 11 2001 3099 3102
66. A.E. Koch, S.E. Kunkel, S.E. Harlow, D.D. Mazarakis, G.K. Haines, and M.D. Burdick Macrophage inflammatory protein-1α. A novel chemotactic cytokine for macrophages in rheumatoid arthritis J Clin Invest 93 1994 921
67. S. Kumar, G.Y. Kwei, G.K. Poon, S.A. Iliff, Y. Wang, and Q. Chen Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein J Pharmacol Exp Ther 304 2003 1161 1171
68. M. Liang, C. Mallari, M. Rosser, H.P. Ng, K. May, and S. Monahan Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1 J Biol Chem 275 2000 19000 19008
69. P. Loetscher, M. Seitz, M. Baggiolini, and B. Moser Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes J Exp Med 184 1996 569 577
70. C.L. Lynch, A.L. Gentry, J.J. Hale, S.G. Mills, M. MacCoss, and L. Malkowitz CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines Bioorg Med Chem Lett 12 2002 677 679
71. C.L. Lynch, J.J. Hale, R.J. Budhu, A.L. Gentry, S.G. Mills, and K.T. Chapman 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: Part 4. Synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV Bioorg Med Chem Lett 12 2002 3001 3004
72. C.L. Lynch, J.J. Hale, R.J. Budhu, A.L. Gentry, P.E. Finke, and C.G. Caldwell CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity Org Lett 5 2003 2473 2475
73. C.L. Lynch, C.A. Willoughby, J.J. Hale, E.J. Holson, R.J. Budhu, and A.L. Gentry 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains Bioorg Med Chem Lett 13 2003 119 123
74. K. Maeda, H. Nakata, Y. Koh, T. Miyakawa, H. Ogata, and Y. Takaoka Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro J Virol 78 2004 8654 8662
75. P. Matthys, S. Hatse, K. Vermeire, A. Wuyts, G. Bridger, and G.W. Henson Amd3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor cxcr4, inhibits autoimmune joint inflammation in ifn-gamma receptor-deficient mice J Immunol 167 2001 4686 4692
76. McMaster, B. E. (2003). Anti-inflammatory compositions and methods of use. Patent Application WO2003105857 A1.
77. Millenium (2004). R and D at Millenium. Available at: http://www.mlnm.com/rd/inflammation/candidates/ccr1.asp
78. Miller, M. W., & Scott, J. D. (2002). Piperidine derivatives useful as CCR5 antagonists. Patent Application US20040132711 A1.
79. C. Moller, T. Stromberg, M. Juremalm, K. Nilsson, and G. Nilsson Expression and function of chemokine receptors in human multiple myeloma Leukemia 17 2003 203 210
80. J.P. Moore, S.G. Kitchen, P. Pugach, and J.A. Zack The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection AIDS Res Hum Retroviruses 20 2004 111 126
81. A. Naya, Y. Sagara, K. Ohwaki, T. Saeki, D. Ichikawa, and Y. Iwasawa Design, synthesis, and discovery of a novel CCR1 antagonist J Med Chem 44 2001 1429 1435
82. A. Naya, M. Ishikawa, K. Matsuda, K. Ohwaki, T. Saeki, and K. Noguchi Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists Bioorg Med Chem 11 2003 875 884
83. J. Pattison, P.J. Nelson, P. Huie, I. von Leuttichau, G. Farshid, and R.K. Sibley RANTES chemokine expression in cell-mediated transplant rejection of the kidney Lancet 343 1994 209 211
84. Pennell, A. M. K., Aggen, J. B., Wright, J. J. K., Sen, S., McMaster, B. E., & Dairhaghi, D. J. (2003). 1-Aryl-4-substituted piperazines derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders. Patent Application WO2003105853 A1.
85. Pennell, A. M. K., Aggen, J. B., Wright, J. J. K., McMaster, B. E., Sen, S., & Dairhaghi, D. J. (2004). Substituted piperazines. Patent Application US20040162282 A1.
86. Pfizer A Prescription for Access 2004 < www.pfizer.com/subsites/ philanthropy/access/access_spring_2004.pdf >
87. C. Plater-Zyberk, A.J. Hoogewerf, A.E. Proudfoot, C.A. Power, and T.N. Wells Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice Immunol Lett 57 1997 117 120
88. M.P. Quinones, S.K. Ahuja, F. Jimenez, J. Schaefer, E. Garavito, and A. Rao Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis J Clin Invest 113 2004 856 866
89. R.M. Ransohoff, and K.B. Bacon Chemokine receptor antagonism as a new therapy for multiple sclerosis Expert Opin Investig Drugs 9 2000 1079 1097
90. P. Rathanaswami, M. Hachicha, M. Sadick, T.J. Schall, and S.R. McColl Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines J Biol Chem 268 1993 5834 5839
91. G. Reyes Development of CCR5 antagonists as a new class of anti-HIV therapeutic Abstract L11 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL 2001
92. J.B. Rottman, A.J. Slavin, R. Silva, H.L. Weiner, C.G. Gerard, and W.W. Hancock Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent Eur J Immunol 30 2000 2372 2377
93. M. Ruster, H. Sperschneider, R. Funfstuck, G. Stein, and H.J. Grone Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts Clin Nephrol 61 2004 30 39
94. J.H. Ruth, J.B. Rottman, K.J. Katschke Jr., S. Qin, L. Wu, and G. LaRosa Selective lymphocyte chemokine receptor expression in the rheumatoid joint Arthritis Rheum 44 2001 2750 2760
95. T. Saeki, and A. Naya CCR1 chemokine receptor antagonist Curr Pharm Des 9 2003 1201 1208
96. K. Schreiber, A.B. Otura, L.P. Ryder, H.O. Madsen, O.S. Jorgensen, and A. Svejgaard Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E) Mult Scler 8 2002 295 298
97. D. Schurmann, R. Rouzier, R. Nougarede, J. Reynes, G. Fatkenheuer, and F. Raffi SCH D: antiviral activity of a CCR5 receptor antagonist 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA 2003
98. M.K. Schwarz, and T.N. Wells New therapeutics that modulate chemokine networks Nat Rev Drug Discov 1 2002 347 358
99. F. Sellebjerg, H.O. Madsen, C.V. Jensen, J. Jensen, and P. Garred CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis J Neuroimmunol 102 2000 98 106
100. K.R. Shadidi, K.M. Thompson, J.E. Henriksen, J.B. Natvig, and T. Aarvak Association of antigen specificity and migratory capacity of memory T cells in rheumatoid arthritis Scand J Immunol 55 2002 274 283
101. S. Shahrara, M.A. Amin, J.M. Woods, G.K. Haines, and A.E. Koch Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis Arthritis Rheum 48 2003 3568 3583
102. K. Shankaran, K.L. Donnelly, S.K. Shah, C.G. Caldwell, P. Chen, and P.E. Finke Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl- pentylsulfones as CCR5 antagonists Bioorg Med Chem Lett 14 2004 3589 3593
103. K. Shankaran, K.L. Donnelly, S.K. Shah, R.N. Guthikonda, M. MacCoss, and S.G. Mills Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)- pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor Bioorg Med Chem Lett 14 2004 3419 3424
104. D.M. Shen, M. Shu, S.G. Mills, K.T. Chapman, L. Malkowitz, and M.S. Springer Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains: Part 1. Discovery and SAR study of 4-pyrazolylpiperidine side chains Bioorg Med Chem Lett 14 2004 935 939
105. D.M. Shen, M. Shu, C.A. Willoughby, S. Shah, C.L. Lynch, and J.J. Hale Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains: Part 2. Discovery of potent, selective, and orally bioavailable compounds Bioorg Med Chem Lett 14 2004 941 945
106. N. Snowden, A. Hajeer, W. Thomson, and B. Ollier RANTES role in rheumatoid arthritis Lancet 343 1994 547 548
107. T.L. Sorensen, M. Tani, J. Jensen, V. Pierce, C. Lucchinetti, and V.A. Folcik Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients J Clin Invest 103 1999 807 815
108. S. Struyf, P. Proost, D. Schols, E. De Clercq, G. Opdenakker, and J.P. Lenaerts CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3 J Immunol 162 1999 4903 4909
109. E.H. Tran, W.A. Kuziel, and T. Owens Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor Eur J Immunol 30 2000 1410 1415
110. C. Trebst, T.L. Sorensen, P. Kivisakk, M.K. Cathcart, J. Hesselgesser, and R. Horuk CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis Am J Pathol 159 2001 1701 1710
111. C. Trebst, T.L. Sorensen, P. Kivisakk, M.K. Cathcart, J. Hesselgesser, and R. Horuk Chemokine receptors on mononuclear phagocytes in the central nervous system of patients with multiple sclerosis Ernst Schering Res Found Workshop 39 2002 193 211
112. A. Trkola, S.E. Kuhmann, J.M. Strizki, E. Maxwell, T. Ketas, and T. Morgan HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use Proc Natl Acad Sci U S A 99 2002 395 400
113. P.A. Volberding Advances in the medical management of patients with HIV-1 infection: an overview Aids 13 Suppl. 1 1999 S1 S9
114. C.A. Willoughby, S.C. Berk, K.G. Rosauer, S. Degrado, K.T. Chapman, and S.L. Gould Combinatorial synthesis of CCR5 antagonists Bioorg Med Chem Lett 11 2001 3137 3141
115. C.A. Willoughby, K.G. Rosauer, J.J. Hale, R.J. Budhu, S.G. Mills, and K.T. Chapman 1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains Bioorg Med Chem Lett 13 2003 427 431
116. I. Zapico, E. Coto, A. Rodriguez, C. Alvarez, J.C. Torre, and V. Alvarez CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis Genes Immun 1 2000 288 289
117. D. Zhao, D.I. Lebovic, and R.N. Taylor Long-term progestin treatment inhibits RANTES (regulated on activation, normal T cell expressed and secreted) gene expression in human endometrial stromal cells J Clin Endocrinol Metab 87 2002 2514 2519